<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04238169</url>
  </required_header>
  <id_info>
    <org_study_id>XQonc-014</org_study_id>
    <nct_id>NCT04238169</nct_id>
  </id_info>
  <brief_title>Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC</brief_title>
  <official_title>Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, open-label study to observe the effect of SBRT and&#xD;
      immunotherapy combined with Bevacizumab or not in stage IV non-squamous non-small cell lung&#xD;
      cancer (NSCLC) with previously failed after chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Assess the efficacy (overall response rate [ORR]) of SBRT and Toripalimab combined with Bevacizumab or not in stage IV non-squamous NSCLC with previously failed after chemotherapy. (according to RECIST version 1.1 and EORTC 1999)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response of non-target lesion</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Assess the efficacy (Objective response of non-target lesion) of SBRT and Toripalimab combined with Bevacizumab or not in stage IV non-squamous NSCLC with previously failed after chemotherapy. (according to RECIST version 1.1 and EORTC 1999)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From date of first dose of study drug until disease progression, withdrawal of consent, death, new anti-cancer therapy (up to approximately 2 years)</time_frame>
    <description>Estimate the progression-free survival (PFS) in patients with NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From date of first dose of study drug until disease progression, withdrawal of consent, death, new anti-cancer therapy (up to approximately 2 years)</time_frame>
    <description>Duration from the first time reported partial response or complete response to the first time of disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of first dose of study drug until withdrawal of consent or death (up to approximately 2 years)</time_frame>
    <description>Duration from the date of initial treatment to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse events (AEs) as a measure of safety</measure>
    <time_frame>For each participant, from the first participant first dose until 30 days after the last dose (up to approximately 2 years)</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical investigation participant administered an investigational product. Safety and tolerance evaluated by incidence, severity and outcomes of AEs (according to NCI-CTCAE 5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From date of first dose of study drug until disease progression, withdrawal of consent, death, new anti-cancer therapy (up to approximately 2 years)</time_frame>
    <description>Patient-Reported Outcomes collected via the EORTC QLQ-C30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-Small-Cell Lung Cancer Stage IV</condition>
  <arm_group>
    <arm_group_label>SBRT+Toripalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunotherapy：Toripalimab: 240 mg once every three weeks，Until progress of disease or investigators determine that clinical benefit is no longer available or there are intolerable toxicity.&#xD;
SBRT：30-50Gy/5F（2-4 locations).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT+Bevacizumab+Toripalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunotherapy：Toripalimab: 240 mg once every three weeks，Until progress of disease or investigators determine that clinical benefit is no longer available or there are intolerable toxicity.&#xD;
SBRT：30-50 Grays(Gy) in 5 fractions（2-4 locations）. Bevacizumab：7.5mg/kg once every three weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>7.5mg/kg once every three weeks</description>
    <arm_group_label>SBRT+Bevacizumab+Toripalimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>240 mg once every three weeks</description>
    <arm_group_label>SBRT+Bevacizumab+Toripalimab</arm_group_label>
    <arm_group_label>SBRT+Toripalimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>30-50Gy/5F（2-4 lesions）</description>
    <arm_group_label>SBRT+Bevacizumab+Toripalimab</arm_group_label>
    <arm_group_label>SBRT+Toripalimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must have signed written informed consent and able to comply with study procedures.&#xD;
&#xD;
          2. Histologically and/or cytologically confirmed advanced metastatic (stage IV)&#xD;
             non-squamous non-small cell lung cancer.&#xD;
&#xD;
          3. Previous received first-line platinum-based chemotherapy or immunotherapy (except&#xD;
             toripalimab) and followed by progression of disease evaluated by RECIST 1.1.&#xD;
&#xD;
          4. Age ≥ 18 years.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) Performance Status score 0-1.&#xD;
&#xD;
          6. Life expectancy ≥ 12 weeks.&#xD;
&#xD;
          7. Have at least 3 measurable lesions based on RECIST 1.1, at least 2 of them can be&#xD;
             treated by SBRT.&#xD;
&#xD;
          8. Adequate hematologic function as defined by the following laboratory values:&#xD;
&#xD;
               -  Absolute neutrophil count ≥1.5x109/L&#xD;
&#xD;
               -  Platelets ≥80 x 109/L&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL&#xD;
&#xD;
               -  Adequate Hepatic function: Total bilirubin ≤1.5×ULN Aspartate aminotransferase&#xD;
                  (AST) and alanine aminotransferase (ALT) ≤2.5×ULN OR ≤5×ULN for patients with&#xD;
                  liver metastases.&#xD;
&#xD;
          9. Adequate renal function: Creatinine ≤1.5×ULN or calculated creatinine clearance (CrCl)&#xD;
             ≥50 mL/min and dipstick proteinuria &lt;2+. A 24-hour urine protein test is needed if a&#xD;
             dipstick proteinuria result of ≥2+ is detected, the proteinuria level ≤ 1g/24h.&#xD;
&#xD;
         10. International normalized ratio≤1.5 × ULN, prothrombin time (PT) or partial&#xD;
             thromboplastin time (PTT or a PTT) ≤1.5 × ULN(within 7 days of assessment).&#xD;
&#xD;
         11. Female who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or&#xD;
             surgically sterile must be willing to use an adequate method of contraception.&#xD;
&#xD;
         12. Male subjects of childbearing potential must agree to use an adequate method of&#xD;
             contraception (failure rate &lt; 1% per year) - Contraception, starting with the first&#xD;
             dose of study therapy through 6 months after the last dose of study therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of tumour invading major blood vessels on imaging. The investigator or the&#xD;
             local radiologist must exclude evidence of tumour that is fully contiguous with,&#xD;
             surrounding, or extending into the lumen of a major blood vessel (e.g., pulmonary&#xD;
             artery or superior vena cava).&#xD;
&#xD;
          2. Core biopsy or other minor surgical procedure, excluding placement of a vascular&#xD;
             access device are excluded within 7 days prior to initiation of study treatment.&#xD;
             Placement of a vascular access device should be at least 2 days prior to initiation of&#xD;
             study treatment.&#xD;
&#xD;
          3. Current or recent (within 10 days of first dose of bevacizumab) use of aspirin (325&#xD;
             mg/day) or other nonsteroidal anti-inflammatory agents known to inhibit platelet&#xD;
             function.&#xD;
&#xD;
          4. Current or recent (within 10 days of first dose of bevacizumab) use of full-dose oral&#xD;
             or parenteral anticoagulants or thrombolytic agent for therapeutic purposes.&#xD;
             Prophylactic use of anticoagulants is allowed.&#xD;
&#xD;
          5. History or evidence of inherited bleeding diathesis or coagulopathy that increases the&#xD;
             risk of bleeding.&#xD;
&#xD;
          6. Uncontrolled hypertension (blood pressures: systolic&gt;150 mmHg and/or diastolic &gt;100&#xD;
             mmHg).&#xD;
&#xD;
             Prior history of hypertensive crisis or hypertensive encephalopathy.&#xD;
&#xD;
          7. Clinically significant (i.e., active) cardiovascular disease, including but not&#xD;
             limited to cerebral vascular accident (CVA) or (transient ischemic attack) TIA (≤6&#xD;
             months before randomization), myocardial infarction (≤6 months before randomization),&#xD;
             unstable angina, congestive heart failure New York Heart Association Class≥II, or&#xD;
             serious cardiac arrhythmia requiring medication during the study and that might&#xD;
             interfere with regularity of the study treatment or not controlled by medication.&#xD;
&#xD;
          8. Significant vascular disease (including but not limited to aortic aneurysm requiring&#xD;
             surgical repair or recent arterial thrombosis) within 6 months prior to randomization.&#xD;
&#xD;
          9. The lesion has received prior radiotherapy and is not suitable for SBRT.&#xD;
&#xD;
         10. Has stable brain metastases is allowed, but the brain metastases will not receive SBRT&#xD;
             or whole brain radiotherapy (WBRT)&#xD;
&#xD;
         11. Malignancies other than NSCLC within 2 years except for basal or squamous cell skin&#xD;
             cancer, carcinoma in situ of the cervix and cured early stage prostate cancer.&#xD;
&#xD;
         12. Corticosteroid therapy at a dose equivalent to 10 mg prednisone per day or any other&#xD;
             systemic immunosuppressive therapy within 14 days prior to randomization. Topical or&#xD;
             inhaled steroids are permitted. Taking immunosuppressive drugs accidentally during the&#xD;
             trial will be allowed, but it is strongly recommended to reduce the dose as soon as&#xD;
             possible.&#xD;
&#xD;
         13. A positive HIV test result, presence of active HIV, hepatitis B or hepatitis&#xD;
             C（evaluate at local laboratories）&#xD;
&#xD;
         14. Non-healing wound, active peptic ulcer, or bone fracture.&#xD;
&#xD;
         15. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 6 months of enrollment.&#xD;
&#xD;
         16. Pregnant or lactating, or intending to become pregnant during the study.&#xD;
&#xD;
         17. Treatment with any other investigational agent or participation in another clinical&#xD;
             trial within 28 days prior to randomization.&#xD;
&#xD;
         18. Evidence of ongoing or active infection requiring IV antibiotics; any other disease,&#xD;
             neurological, or metabolic dysfunction; physical examination finding or laboratory&#xD;
             finding giving reasonable suspicion of a disease or condition that contraindicates the&#xD;
             use of an investigational drug or puts the patient at high risk for treatment-related&#xD;
             complications.&#xD;
&#xD;
         19. Patients diagnosed with a tracheo-oesophageal fistula.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianguo Sun</last_name>
    <phone>02368763452</phone>
    <email>sunjg09@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xinqiao Hospital of Chongqing</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun Jianguo</last_name>
      <phone>02368763452</phone>
      <email>sunjg09@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Jianguo Sun</investigator_full_name>
    <investigator_title>director physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

